Advertisement
Screener

EVOLUS, INC. (EOLS) Graph

EOLS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $84.08M; Cost of revenue $26.90M; Research and development (m); Selling, general and administrative $57.05M.
  • 2026-03-31: Revenue $73.14M; Cost of revenue $24.24M; Research and development (m); Selling, general and administrative $51.98M.
  • 2025-12-31: Revenue $90.30M*; Cost of revenue $31.01M*; Research and development (m); Selling, general and administrative $54.66M*.
  • 2025-09-30: Revenue $68.97M; Cost of revenue $23.13M; Research and development (m); Selling, general and administrative $52.82M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

EOLS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$83.35MService$734.00KRevenue$84.08MCost of revenue$26.90MGross profit$57.18MOperating income-$4.54MOther income, net$213.00KSelling, general& administrative$57.05MPre-tax income-$8.21MIncome tax-$154.00KNet income-$8.05M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

EOLS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$84.08MRevenue$84.08MCost of revenue$26.90MGross profit$57.18MOperating income-$4.54MOther income, net$213.00KSelling, general& administrative$57.05MPre-tax income-$8.21MIncome tax-$154.00KNet income-$8.05M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$84.08M$26.90M(m)$57.05M(m)-$154.00K-$8.05M
2026-03-31$73.14M$24.24M(m)$51.98M(m)$256.00K-$10.67M
2025-12-31$90.30M*$31.01M*(m)$54.66M*(m)$385.00K*$130.00K*
2025-09-30$68.97M$23.13M(m)$52.82M(m)$167.00K-$15.74M
2025-06-30$69.39M$24.07M(m)$56.67M(m)$53.00K-$17.14M
2025-03-31$68.52M$21.87M(m)$56.64M(m)$72.00K-$18.89M
2024-09-30$61.09M$18.99M(m)$52.51M(m)$134.00K-$19.17M
2024-06-30$66.91M$19.84M(m)$50.15M(m)$43.00K-$11.35M
2024-03-31$59.33M$18.83M(m)$45.12M(m)$47.00K-$13.11M
2023-09-30$50.02M$15.43M(m)$43.33M(m)$24.00K-$16.92M
2023-06-30$49.35M$14.71M(m)$41.17M(m)$23.00K-$18.14M
2023-03-31$41.72M$12.15M(m)$37.38M(m)$23.00K-$14.79M
2022-09-30$33.90M$13.49M(m)$34.79M(m)$12.00K-$20.28M
2022-06-30$37.16M$15.82M(m)$36.88M(m)$28.00K-$23.47M
2022-03-31$33.91M$13.21M$468.00K$33.44M(m)-$2.00K-$17.50M
2021-12-31(m)(m)$423.00K*(m)(m)(m)(m)
2021-09-30$26.68M$11.49M$301.00K$31.67M(m)$12.00K-$19.43M
2021-06-30$26.10M$11.30M$499.00K$26.46M(m)$9.00K-$15.60M
2021-03-31$12.24M$4.91M$841.00K$20.66M(m)$12.00K$6.40M
2020-09-30$17.66M$4.85M$350.00K$21.94M$21.57M-$27.00K-$11.46M
2020-06-30$7.81M$1.95M$145.00K$17.55M$24.75M-$2.00K-$21.13M
2020-03-31$10.50M$4.22M$507.00K$31.30M$23.67M$256.00K-$19.73M
2019-09-30$13.17M$3.72M$693.00K$30.90M$34.59M-$149.00K-$26.98M
2019-06-30$2.31M$660.00K$509.00K$34.89M$37.65M-$227.00K-$37.57M
2019-03-31$0.00$0.00$2.35M$17.52M$25.27M-$14.52M-$10.97M
2018-09-30$0.00$0.00$1.98M$7.21M$11.49M$19.00K-$11.83M
2018-06-30$0.00$0.00$1.65M$6.25M$16.10M$12.00K-$16.43M
2018-03-31(m)(m)$1.68M(m)$6.04M$10.00K-$6.16M
2017-09-30(m)(m)$1.47M(m)$2.62M$16.00K-$2.63M
2017-06-30(m)(m)$1.36M(m)$2.27M$20.00K-$2.30M
2017-03-31(m)(m)$2.65M(m)$3.98M$20.00K-$4.00M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$157.22M$51.14M(m)$109.03M(m)$102.00K-$18.73M
2025-06-30$137.91M$45.93M(m)$113.31M(m)$125.00K-$36.03M
2024-06-30$126.24M$38.67M(m)$95.28M(m)$90.00K-$24.46M
2023-06-30$91.07M$26.86M(m)$78.56M(m)$46.00K-$32.93M
2022-06-30$71.07M$29.03M(m)$70.32M(m)$26.00K-$40.97M
2021-06-30$38.34M$16.21M$1.34M$47.13M(m)$21.00K-$9.20M
2020-06-30$18.30M$6.17M$653.00K$48.85M$48.42M$254.00K-$40.86M
2019-06-30$2.31M$660.00K$2.86M$52.41M$62.92M-$14.75M-$48.54M
2018-06-30$0.00$0.00$3.33M$9.71M$22.14M$22.00K-$22.59M
2017-06-30(m)(m)$4.02M(m)$6.25M$40.00K-$6.29M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$206.88M$69.06M(m)$166.13M(m)$292.00K-$51.77M
2024-09-30$187.33M$57.66M(m)$147.78M(m)$224.00K-$43.63M
2023-09-30$141.09M$42.29M(m)$121.89M(m)$70.00K-$49.85M
2022-09-30$104.97M$42.52M(m)$105.11M(m)$38.00K-$61.25M
2021-09-30$65.02M$27.70M$1.64M$78.80M(m)$33.00K-$28.63M
2020-09-30$35.96M$11.02M$1.00M$70.80M$69.98M$227.00K-$52.32M
2019-09-30$15.48M$4.38M$3.56M$83.31M$97.50M-$14.90M-$75.53M
2018-09-30$0.00$0.00$5.30M$16.92M$33.63M$41.00K-$34.42M
2017-09-30(m)(m)$5.48M(m)$8.87M$56.00K-$8.93M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$297.18M$100.07M(m)$220.79M(m)$677.00K-$51.64M
2024-12-31$266.27M$83.97M(m)$198.03M(m)$664.00K-$50.42M
2023-12-31$202.09M$64.51M(m)$164.94M(m)$176.00K-$61.69M
2022-12-31$148.62M$58.84M(m)$141.84M(m)$95.00K-$74.41M
2021-12-31$99.67M$43.53M$2.06M$112.07M(m)$42.00K-$46.81M
2020-12-31$56.54M$18.30M$1.72M$98.19M(m)$77.00K-$163.01M
2019-12-31$34.92M$8.01M$3.97M$113.59M$125.86M-$15.03M-$90.03M
2018-12-31$0.00$0.00$6.49M$29.15M$46.14M$65.00K-$46.87M
2017-12-31(m)(m)$6.69M(m)$11.73M-$7.25M-$4.48M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ARVINAS, INC. (ARVN)United States$0.510B58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Altimmune, Inc. (ALT)United States$0.593B-6.43